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Identifying a topic to compose my master’s thesis upon was a thought-provoking exercise. 
 
During my second-year assignment I completed a quantitative survey and worked with 
statistical analysis and interpretations. Conversely, this year, I knew I wanted to do a literary 
review to improve my research and writing skills on scientific and evidence-based medicine. 
By conducting a literary review, I intend to develop and master my understanding of 
recognized medical databases, like Cochrane, Embase and Medline, which upon completion, 
should prove to become a significant asset when I come to treat my own patients in the 
future. 
 
To achieve this, I desired a topic that challenged me, I knew little about and most 
importantly, fascinated me, because this was something I would be pursuing for almost a 
year. I recall while on exchange in Melbourne, Australia at The Royal Women’s Hospital last 
year, the pediatricians mentioned caffeine for treating apnea in premature babies. The 
treatment was said to help their immature lungs develop faster. Prior to my exchange, I 
understood pregnant women should restrict their caffeine intake as too much could damage 
the fetus or lead to miscarriage. I found this to be a bit conflicting and perplexing to me. In 
this, I discovered an interesting topic. I determined I wanted to direct further research into 
this caffeine treatment to check for benefits and possible side effects in comparison with 
any placebo and/or other available treatments. 
 
My thesis has not required any financial support nor needed any request to REK (Regional 
Committees for medical and Health Research Ethics) as this is a literary review.  
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Premature infants with pulmonary complications is becoming a substantial health care 
problem. AOP being one of the biggest challenges that may end in death with no or wrongful 
treatment. Non-invasive respiratory support has been the favorable alternative, and caffeine 
citrate has been the drug of choice since the 1970s. The aim of this study is to explore how 
effective caffeine is for treating apnea in premature babies, but also to assess possible side 
effects.  
 
Material and method: 
A systematic literature search was performed in PubMed, Embase, MEDLINE and Cochrane 
around mid-August of 2020. The search was based around a PICO format with the use of 
MeSH-terms. To begin with, 455 articles were identified, but after removing duplets and 
screening with advanced options (only full-text, language and year), 76 articles remained. 
These were skimmed superficially by the abstract, and eventually 30 articles were included 
in the review. 
 
Results: 
Caffeine is effective in reducing and eliminating apnea episodes. It reduced BPD in VLBW 
preterm infants with AOP, the need of supplemental oxygen and the need for positive 
airway pressure. It improved survival rates without neurodevelopmental disability at 18-21 
months in infants with VLBW. Caffeine therapy reduced the incidence of cerebral palsy, 
death and survival rates with neurodevelopmental disability. Neonates receiving caffeine at 
an earlier stage stayed shorter in the NICUs and were less likely to need ventilation. A side 
effect was temporarily reduced weight gain. Some studies showed that caffeine increased 
heart rate.  
 
Conclusion and consequences:  
In preterm infants, caffeine is effective in reducing AOP, the need for ventilation and 
enhances the success of extubation. As caffeine has been the golden standard for four 
decades, it is safe to say it has a respected benefit risk ratio. However, additional larger 
studies are needed to discover potentially rarer adverse side effects. 
 
Key words: 








- Apnea: A transient absence of spontaneous respiration. 
- AOP = Apnea of Prematurity  
- BP = Blood Pressure  
- BPD = Bronchopulmonary Dysplasia: A chronic lung disease developed after oxygen 
inhalation therapy or mechanical ventilation, usually occurring in certain premature 
infants, or newborn infants with respiratory distress syndrome. Histologically, it is 
characterized by the unusual abnormalities of the bronchioles, such as metaplasia, 
decrease in alveolar number, and formation of cysts. 
- Caffeine: A methylxanthine naturally occurring in some beverages and also used as a 
pharmacological agent. Caffeine's most notable pharmacological effect is as a central 
nervous system stimulant, increasing alertness and producing agitation. It also 
relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears 
to be useful in the treatment of some types of headache.  
- CAP = Caffeine for treating Apnea of Prematurity 
- CPAP = Continues Positive Airway Pressure 
- EET = Endo Tracheal Tube  
- FDA = United States Food and Drug Administration: An agency of the PUBLIC 
HEALTH SERVICE concerned with the overall planning, promoting, and administering 
of programs pertaining to maintaining standards of quality of foods, drugs, 
therapeutic devices, etc. 
- GA = Gestational Age: The age of the conceptus, beginning from the time of 
fertilization. In clinical obstetrics, the gestational age is often estimated as the time 
from the last day of the last menstruation which is about 2 weeks before ovulation 
and fertilization. 
- GW = Gestational Week 
- Infant: A child between 1 and 23 months of age 
- NICU = Neonatal Intensive Care Units: Hospital units providing continuing 
surveillance and care to acutely ill newborn infants. 
- NEC = Necrotizing Enterocolitis  
- NNT = Numbers Needed to Treat  
- PDA = Patent Ductus Arteriosus: A congenital heart defect characterized by the 
persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY 
ARTERY to the descending aorta allowing unoxygenated blood to bypass the lung and 
flow to the PLACENTA. Normally, the ductus is closed shortly after birth. 
- PMA = Post Menstrual Age: Gestational age plus chronological age 
- PPV = Positive Pressure Ventilation  
- Premature birth: Childbirth before 37 weeks of pregnancy (259 days from the first 
day of the mother's last menstrual period, or 245 days after fertilization). 
- ROP = Retinopathy of prematurity 
- VLBW = Very Low Birth Weight: An infant whose weight at birth is less than 1500 
grams (3.3 lbs), regardless of gestational age. 
 
 





1 Introduction  
 
1.1 Background: Caffeine 
Caffeine, also known as 1,3,7-trimethylxanthine, is a stable alkaloid  
and a mild stimulant of the central nervous system. It originated from 
Africa more than a millennium ago, and has ever since been used to  
improve people’s mood (1, p. 10). The active ingredient has been added to a wide variety of 
products like soft and energy drinks, chocolate, hair as well as skin care products, and many 
medications; particularly for treating pain, headache and apnea of prematurity (AOP).  
 
The US Food and Drug Administration (FDA) consider a daily amount of about 400 mg of 
caffeine (4-5 cups of coffee), as being a safe amount for healthy adults. For pregnant women 
200 mg apply (1-2 cups of coffee) (2). Studies have shown that by increasing the dose to 300 
mg, the risk of miscarriage increases by 37%, and at 600 mg the risk increases exponentially 
by 250% (3). 
 
The mean half-life of caffeine is found to be 5 hours in adults (4). In preterm babies however 
it is significantly longer. In a study done by Doyle et al in 2016, the authors found that for 
preterm infants at 35 ± 1 week postmenstrual age (PMA), caffeine had a half-life of 87 ± 25 h 
(5). Caffeine has been the gold-standard treatment in the neonatal intensive care unit for 
the past 40 years (6), and is thought to be safe and effective in treating apneas.  
 
1.2 Definitions  
• Apnea: a period of not breathing.  
In premature babies this accounts for pauses lasting longer than 20 seconds.  
Symptoms:   - Bradycardia (heart rate less than 80-100 bpm)  
    - Cyanosis (bluish discoloration of skin or mucous membranes) 
   - Low oxygen saturation (< 85% SaO2 without receiving excess O2) (7) 
• Preterm babies: born before 37 weeks of gestation (8) 
Figure 2: The chemical 
structure of caffeine 
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1.3 Epidemiology of babies with apnea  
For term-born infants, only 1-2% are born with apnea (9). For late preterm neonates (34-36 
weeks’ gestation) the incidence is a little higher, 4-7%. Contrariwise, ≥ 84% with fetal weight 
< 1000 grams / gestational age (GA) <29 weeks, are born with AOP. The same is true for 54% 
of babies between 30-31 weeks’ GA, and 15% of babies at 32-33 weeks’ GA (10). This 
demonstrates that the incidence of AOP is inversely proportional with GA and birth weight.  
 
1.4 Lung development and physiology  
 
Table  1: Lung Development and Physiology 
 
It is important to notice that surfactant, produced by type 2 alveolar epithelial cells, is 
essential to reduce surface tension and for gas exchange to take place. It is produced 
starting around week 23 of gestation (11). Near the end of this canalicular phase, initial gas 
exchange may occur and it is possible for prematurely born babies to survive. Other 
important factors for lung development is adequate space, fetal breathing movements and 
sufficient amniotic fluid. Maturation can be stimulated by glucocorticoids, beta-adrenergic 
agonists & thyroid hormones, as well as caffeine citrate (12). 
  
Lung development is divided into three phases (11) 
Phase Period Development 
1) Embryonic 4-7 weeks GA Specifies lung organogenesis with two lungs. Formation 
of major airways and pleura. 
2) Fetal (divided into three stages):  
Pseudoglandular 5-17 weeks GA Formation of airways with bronchial tree and 
respiratory parenchyma. Start of the acinus. 
Canalicular 16-26 weeks GA Finishes formation of acini (operative part for gas 
exchange) due to epithelial differentiation. The most 
distal airways are being completed with air-blood 
barrier. Surfactant appears. 
Saccular 24-38 weeks GA Further progression of upcoming airspaces. 
3) Postnatal 36-weeks GA  
to 4 years 
Continuation of alveolar proliferation. Establishing 




1.5 Caffeine citrate - mechanism of action  
Caffeine works by inhibiting adenosine A1 and A2 receptors (the resting/sleep receptors) 
and stimulates catecholamine release. This in turn leads to a feeling of well-being, better 
mood, more energy, increased ability to stay focused and delays the need of sleep. Caffeine 
may also improve certain cognitive functions (13). Nonetheless, it is classified as a doping 
substance by the International Olympic Committee as it increases physical endurance, with 
the upper limit of urine concentration being 12 µg / ml (14). 
 
The lethal dose is estimated to be around 5-10 grams. However, with a chronic intake of 
more than 500 mg daily (approx. 1 L of coffee), intoxication can occur. Intoxication is 
associated with anxiety, irritability, chronic insomnia, anorexia and low grade fever. Caffeine 
can also aggravate symptoms that people with cardiac arrhythmias (tachyarrhythmia) and 
dyspepsia experience (14). 
 
Another mechanism of action with higher dosages is inhibition of phosphodiesterase. This in 
turn leads to inactivation of cAMP (the 2nd messenger for activating adrenoceptors) and 
increases intracellular cAMP. The result enhances adrenoceptor activity and thus 
bronchodilation. They can also produce anti-inflammatory effects by inhibiting the signaling 
protein TNF-alpha (tumor necrosis factor alpha) (15). 
 
Caffeine also stimulates peripheral chemoreceptors, which in turn initiate normal breathing. 
It may also enhance clearance of ciliary mucosa and increase drive of the diaphragm muscle. 
The active ingredient is both water and fat soluble, meaning it can cross the blood-brain 
barrier. Absorption takes place in the small intestine, entering the bloodstream via the liver 
where it is broken down by cytochrome P450 oxidases, especially CYP1A2 (16).  
 
Caffeine is also shown to increase sensitivity due to high levels of carbon dioxide in the 
bloodstream, leading to elevated metabolic rate, decreased muscle fatigability, and escalate 





1.6 The use of caffeine citrate at The University Hospital of North Norway 
At the University Hospital of North Norway (UNN), Caffeine citrate (Peyona®) is being used 
as first line treatment for AOP. It works by increasing respiration response to pCO2, and has a 
positive effect on respiratory muscles by increasing CNS excitation. Following a bolus dose, 
increased diaphragmatic activity and greater tidal volume is seen in preterm infants. 
Compared to theophylline, caffeine has a greater distance to toxic levels (> 250 micromol/L). 
Moreover, it can be dosed once daily (due to longer half-life), has more reliable enteral 
absorption, gives less side effects, and requires no routine of monitoring serum levels (18). 
 
Administration of Caffeine citrate at UNN (19) 
Loading dose: 20 mg/kg   
Maintenance dose: 5-10 mg/kg.  
Side effects Not common, but might give tachycardia. If pulse reaches > 180 bpm, then 
they lower the dose. 
Discontinuation - Usually at postmenstrual age +/- 34 weeks.  
- Or when the baby is on CPAP and been 5-7 days without significant 
apnea. Can be used longer if needed 




1.7 Aim of current study 
The incidence of preterm babies is increasing globally (20), so is the number of survivors 
(21). As a consequence, a rising number of newborns are growing up with pulmonary 
complications, which are potentially long-term. In fact, it is becoming a substantial health 
care problem (22). AOP is one of the biggest challenges, as this may lead to respiratory 
failure and the need for mechanical ventilation. Ventilation itself could give rise to 
bronchopulmonary dysplasia (BPD), a chronic lung disease.  
 
Premature infants on ventilation can also develop neurological impairments that can 
eventually lead to death (23). This is why non-invasive respiratory support is the favorable 
treatment. Caffeine citrate has been the drug of choice since the 1970s (24). The aim of this 
study is to explore how effective caffeine is for treating apnea in premature babies, but also 
to assess potential side effects.   
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2 Material and Method 
 
2.1 PICO search  
A search strategy was based on the following PICO:  
Population: Preterm babies with apnea 
Intervention: Caffeine 
Comparison: No treatment, placebo, other treatments 
Outcome Primary outcome:  
Beneficial effects of caffeine on treating AOP, including reduced events of AOP, 
fewer days on ventilation and shorter stays at the NICUs.  
Secondary outcome:  
Side effects, including neurodevelopmental occurrences, increased heart rate, 
necrotizing enterocolitis, reduced weight gain, need of ventilation or CPAP.  
Table  3: Pico Search Format 
 
I decided to include all full-text papers in English published after the year of 2000, regardless 
of study design. Exclusion criteria were anything that did not fit the PICO criteria above or 
did not provide an answer to the research question. Thus, RCTs, cohort studies (prospective 
and retrospective) and reviews were included. 
 
 
2.2 MeSH terms  
To include as many articles as possible, a systematic search was prepared operating MeSH 
(Medical Subject Headings) terms.  
 






























2.3 Prisma Flow Chart 
Four databases were used in this systematic literary search; PubMed, Embase, Medline and 
Cochrane. Initially, a total of 455 articles were found using the MeSH terms ‘caffeine’, 
‘apnea’, ‘prematurity’ and ‘infant’. After removing duplicates, 243 articles remained. By 
filtering for English language and full-text-only articles published after the year of 2000, 76 
articles were left. These were manually skimmed by reading the abstract to check if they met 
the inclusion criteria and gave answer to the research question. Finally, 30 articles remained 











3 Results  
 
3.1 The CAP trial 
A study by Schmidt et al (25), one of the largest randomized multicenter placebo-controlled 
trial study on the subject, included a total of 2006 infants weighing in between 500-1250 g  
at birth. They were randomized within the first 10 days of life to receive either caffeine  
(n = 1006) or saline placebo (n = 1000) until therapy was no longer needed. The caffeine 
group received a loading dose of 20 mg/kg at median 3 days of age, and a maintenance dose 
of 5-10 mg/kg until therapy weaned off, which happened before reaching 35 weeks post 
menstrual age (PMA). 
 
The authors found that at PMA of 36 weeks, only 36% (of n = 963, still alive) in the caffeine 
group received supplemental oxygen vs 47% (of n = 954, still alive) in the placebo group  
(p < 0.001). Also, the caffeine group discontinued positive airway pressure 1 week earlier 
than the placebo group, 31 weeks being the median PMA vs 32 weeks PMA (p < 0.001).  
Further, co-interventions with either Doxapram (a respiratory stimulant), postnatal 
corticosteroids, and/or red-cell transfusions were all less frequently used in the caffeine 
group (p < 0.001 for each comparison).  
 
A side effect of caffeine therapy was temporarily reduced weight gain, being largest two 
weeks into therapy with a mean difference of -23 grams (p < 0.001). Death rates, brain 
injuries measured with ultrasonography, and necrotizing enterocolitis (NEC) did not differ 
significantly between the two groups at their first discharge home. 
 
A post-hoc analysis showed that the infants in the caffeine group were significantly less likely 
to undergo surgery to close a patent ductus arteriosus (PDA) vs the placebo group. Since 
their study protocol did not mandate serial echocardiography in all study patients, it is 
uncertain whether caffeine promoted the closure of a patent ductus arteriosus and this 





The authors conclusion was that caffeine reduced bronchopulmonary dysplasia (BPD) in very 
low birth weight (VLBW) preterm infants with AOP, which they defined as not needing 
supplemental oxygen at 36 weeks PMA. Caffeine did not seem to cause any short-term side 
effects except for the temporary reduction in weight gain. When the FDA approved caffeine 
citrate for treating apnea of prematurity, a warning stated that there might be a possible 
association between methylxanthines and development of NEC. The absenteeism of any 
detectible effect of caffeine on NEC in this study is reassuring. 
 
In November 2007 Schmidt et al (26) published a follow-up from their first study. This time 
they were observing possible long-term side effects as the babies turned 18-21 months.  
In total, 937 babies in the caffeine group and 932 in the placebo group had adequate data 
and were eligible for follow-up. Primary outcomes were death, deafness, blindness, cerebral 
palsy, or cognitive delay. Just over 40% of the participants in the caffeine group died or 
survived with a neurodevelopmental disability, which was significantly fewer compared with 
the placebo group; 46.2% (p = 0.008). The number needed to treat (NNT) AOP with caffeine 
to avoid one adverse outcome at 18 months was 16 (95% CI 9-56).  
 
Furthermore, caffeine significantly reduced the incidence of cerebral palsy; only 4.4% in the 
caffeine group compared to 7.3% in the placebo group (p = 0.009). Further, there was a 
significant difference in the incidence of cognitive delay, 33.8% in the caffeine group vs 
38.3% in the placebo group (p = 0.04). Early cessation of any positive airway pressure in the 
caffeine group justified 49% of the beneficial long-term effect. 
 
The death rates, deafness, and blindness and the mean percentiles for height, weight, and 
head circumference at follow-up did not differ significantly between the two groups.  
However, a post-hoc analysis showed reduced incidence of severe eye disease, retinopathy, 
in the caffeine group. Overall, they concluded that caffeine therapy for apnea of prematurity 
improves survival rate without neurodevelopmental disability at 18 - 21 months in infants 
with VLBW.  
 
In 2010, Davis et al published a study (27) to assess if the benefits of caffeine maybe varied 
in subgroups, looking at the participants in the CAP trial. They divided subgroups according 
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to indication for receiving caffeine, being either to prevent or treat apnea, or to facilitate 
removal of an endotracheal tube (EET). They also looked into the levels of respiratory 
support; no support, none-invasive support or ventilation via ETT. Furthermore, they viewed 
the time for commencing the drug; mean PMA being 3 days, early group being before 3 days 
and late being 3 days and beyond.  
 
A total of 1869 infants (93,2%) were included. There was little evidence of a differential 
treatment effect of caffeine. There was, however, indication of heterogeneity of caffeine 
effect for the outcomes death or major disability (p = 0.03) and cognitive delay (P = 0.02). 
Infants receiving respiratory support at the time of randomization appeared to derive 
greater long-term neurological benefits from caffeine than those who did not. The 
differences in PMA at last endotracheal intubation (p = 0.04) and PMA at last positive 
pressure ventilation (PPV) (p = 0.03) were statistically significant. Infants whose treatment 
commenced before 3 days of age appeared to derive greater short-term respiratory benefits 
from caffeine than infants commencing treatment at  3 days. That is, starting caffeine early 
resulted in larger reductions in days on respiratory support.  
 
PMA at the time of discontinuing PPV was shorter with earlier treatment (p = 0.01). Mean 
differences in odds ratio (95% CI) were: early, 1.35 weeks (0.90-1.81); and late 0.55 weeks 
(0.11-0.99). Therefore, the authors concluded that there was evidence of beneficial effects 
of caffeine. Infants receiving respiratory support appeared to derive more 
neurodevelopmental benefits from caffeine than infants not receiving support, and earlier 
initiation of caffeine might have been associated with a greater reduction in time on 
ventilation. 
 
In 2012, a 5-year follow-up was conducted in order to assess long lasting effects (28). 
A total of 1640 children (84.9%) had adequate data for the main outcomes at 5 years of age 
(n= 833 in the caffeine group, n = 807 in the placebo group). The main outcomes were death 
or survival with or without cognitive impairment, behavior problems, health issues, deafness 
and/or blindness. Results showed a lower percentage of death in the caffeine group, 
although borderline not statistically significant (p = 0.09). Most of the other outcomes were 
not significantly different between the two groups.  
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Gross motor impairment was less severe in caffeine-treated children than in controls, and 
they showed better motor coordination and visual perception. The incidence of cognitive 
impairment was strikingly lower at 5 years than 18 months, although still similar in both 
groups (p = 0.89). Nonetheless caffeine had a small continuous favorability. The conclusion 
was that at 5 years of age, neonatal caffeine therapy could no longer be said to have a 
significantly improved survival rate without disability, and that the benefits on survival rates 
without disability at 18 months mitigated during childhood development.   
 
In 2014, a 5-year follow-up randomized controlled trial was conducted by Doyle et al (29), 
exploring developmental coordination disorder (DCD), i.e. motor performance below the 5th 
percentile in children with full scale Intelligence Quotient (IQ) > 69, without being diagnosed 
with cerebral palsy (CP). The rate of DCD was significantly lower in the caffeine group 
(11.3%) compared to the placebo group (15.2%) (p = 0.032), concluding that neonatal 
caffeine therapy for AOP reduced the risk of DCD at 5 years’ age.  
 
Motor dysfunction with or without CP is more common in children born prematurely or with 
low birth weight compared to those born to term. This is important not only for the motor 
impairment per se, but also due to associated problems like cognitive shortages, lower 
academic performance, behavior problems, poor social skills, and self-esteem issues.  
 
In 2017, an 11-Year follow-up (30) of the CAP trial was conducted to evaluate whether or not 
neonatal caffeine therapy was associated with improved functional outcomes 11 years later. 
920 children had adequate data for the follow-up outcomes; academic performance, motor 
impairment and behavioral problems. Their results showed that caffeine therapy was 
associated with a significantly reduced risk of motor impairment compared with placebo (p = 
0.009). There was however no difference in academic performance nor behavioral problems.  
 
In 2018, another 11-year follow-up double-blind randomized placebo-control study (31) was 
conducted to investigate further long term effects. Measurements were fixed on general 
intelligence, attention, executive function, visuomotor integration and perception, and 
behavior, including up to 870 children. The caffeine group performed significantly better 
than placebo in fine motor coordination (p = 0.01) as well as in visuomotor integration (p = 
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0.05), visual perception (p = 0.02) and visuospatial organization (p = 0.003). General 
neurobehavioral outcomes were similar in both groups. None of the secondary outcomes 
reported were adversely affected by caffeine. This highlights the long-term safety of caffeine 
therapy going forward into middle school age. 
 
Taking most of the aforementioned articles into account, neonatal caffeine therapy appears 
to have a lasting beneficial effect on motor function, both at 18 months, 5 and 11 years of 
age. Of preterm infants the NNT with caffeine to prevent one case of moderate to severe 
motor impairment at 11 years of age, was found to be approximately 13. 
 
3.2 Effectiveness of caffeine for treating AOP 
In 2000, Erenberg et al (32) published a multicenter parallel randomized, double-blind, 
placebo-controlled trial with open-label rescue (caffeine citrate rescue arm as the safety net 
for the placebo group). They included 82 preterm infants, 28–32 weeks’ post-conception. 45 
of whom received caffeine citrate solution, 37 received placebo, and both completed 10 
days of double-blind therapy. The caffeine group received 20 mg loading dose followed by 5 
mg/kg/day.  
 
Caffeine citrate was significantly more effective in reducing apnea episodes, by at least 50% 
after 6 days compared to placebo (p < 0.05), and approached statistical significance after 3 
days (p < 0.10). It was also significantly better than placebo in eliminating apnea in 5 days (p 
< 0.05), and approached significance (p < 0.10) after 2 days.  
 
Results showed that 68,9% in the caffeine group vs 43,2% in the placebo group experienced 
a ≥ 50% reduction in apnea episodes (p = 0.02) for an aggregate of 7–10 days of treatment. 
Elimination of apnea happened to 24,4% in the caffeine group vs zero in the placebo group 
(p = 0.005). 
 
To summarize, caffeine citrate in the right given dose is safe and effective for treating apnea 
of prematurity in infants 28–32 weeks postconception. No clinically significant differences 
were found between groups in vital signs, body weight, or laboratory values. In both groups, 
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the increase in mean daily weight was similar during the study. Adverse events were not 
significantly different between the groups.  
 
3.3 Pharmacodynamical effects  
In 2016, Yu et al (33) did a retrospective observational study on 115 preterm infants from 
January 2006 to October 2011. Their aim was to explore the relationship between caffeine 
intake and pharmacodynamics effects on heart rate, respiratory rate, episodes of apnea 
and/or other adverse effects. The infants median age was 29 weeks and birth weight 1230 
grams. Caffeine citrate was given at postnatal age of 1 (1-3) day and therapeutic drug 
monitoring (TDM) was performed at 15 (10-24) days postnatally. No direct correlation was 
found between caffeine serum concentrations and respiratory rate or apneic episodes. 
Though, heart rate and caffeine concentrations were significantly correlated (p < 0.05). 
 
The severity of recorded tachycardia was mostly mild to moderate from 170 – 212 bpm. 
The authors found a significant correlation between caffeine citrate and heart rate (p < 
0.05). The physiological effect was however minor. The regimen 40/5 mg/kg q12h led to 
significantly higher percentage of patients experiencing tachycardia than the standard 
regimen (p < 0.001). No direct correlation between caffeine citrate concentration and 
respiratory rate or apneic episodes was found.  
 
Apneic episodes and onset of adverse events that happened on the same day as TDM were 
measured. None of the neonates died or had any severe reaction under current dosing 
regimens. Out of 115 patients, a total of 27 patients (23.4 %) were re-intubated onto a 
mechanical ventilator during the entire course of caffeine therapy, of which 10 patients (8,6 
%) were re-intubated secondary to worsening symptoms of apnea.  
 
Ulanovsky et al (34) explored caffeine´s effect on the autonomic nervous system with 
regards to treating premature infants with apnea. They prospectively studied 21 preterm 
infants and focused on their heart rate variability. They did not find any changes in heart 
rate, blood pressure nor tone of the autonomic nervous system following caffeine 
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administration. They found no short term detrimental effects on heart rate variability.  
 
Rossor et al (35) studied 26 premature infants to determine if caffeine therapy in premature 
infants could increase ventilator response. They found that caffeine administration 
significantly increased ventilatory response to hypercarbia (n=14, mean difference 41ml/kg/ 
min/% CO2, 95% CI 26–57, p = 0.001). CO2 sensitivity was significantly lower after 
discontinuing caffeine therapy. Furthermore, an initial weaker ventilatory response to 
hypercarbia was associated with the subsequent development of apnea requiring treatment 
with caffeine. 
 
3.4 Caffeine on brain activity  
In 2000, Dani et al published a study (36) looking at hemodynamic changes in the brain of 
preterm infants after maintenance dose of caffeine or aminophylline therapy for treating 
apnea of prematurity. They were measuring cerebral blood flow non-invasively with near-
infrared spectroscopy (NIRS) and cerebral Doppler ultrasonography on 40 infants < 32 GW 
and birth weight < 1500 g. Half received caffeine and the other half aminophylline.  
 
They found that caffeine did not significantly affect brain hemodynamics, including cerebral 
blood flow, heart rate, mean systemic arterial pressure, arterial oxygen saturation, 
transcutaneous carbon dioxide tension nor hemoglobin. While aminophylline induced a 
transient increase in oxygenated and deoxygenated hemoglobin concentration (hence O2Hb 
and HHb) and cerebral blood flow velocity (CBV) in similar extent as caffeine.   
 
In 2014, Hassanein et al published a prospective observational study (37) on 33 preterm 
infant below 34 weeks GA, in Egypt. Their aim was to investigate caffeine’s effect on preterm 
infants’ respiratory functions and brain cortical activity, using conventional-integrated 
electroencephalography (cEEG) and aEEG (amplitude-integrated). Together with 
cardiopulmonary and sleep state, they recorded 20 preterm infants before, during and 2 
hours after intravenous caffeine infusions, and they were controlled against 13 non-
caffeinated preterm infants. They were also measured at 36 weeks’ post-menstrual age as 
an outcome parameter.  
 
 14 
They found significant differences between the groups when it came to increasing heart rate  
(p < 0.001), mean arterial BP (p < 0.001) and capillary SaO2 (p = 0.003) after 30 minutes. They 
didn't find any differences in clinical seizures nor any difference in cEEG, but a significant 
increase in aEEG continuity was detected starting half an hour after caffeine administration 
compared to before (p = 0.002). Furthermore, at 36 weeks’ control, they found significantly 
longer NICU stays in the controls not receiving caffeine (p = 0.022). They concluded that 
caffeine increases cerebral cortical activity and result in maturation at 36 weeks, without risk 
of seizures.  
 
From December 2015 to September 2016, Dix et al included 34 preterm infants (< 32 GA) in 
an observational study (38) at a Wilhelmina children's hospital Utrecht in the Netherlands.  
The babies were neuromonitored using NIRS for surveilling regional cerebral oxygen 
saturation (rScO2) and fractional tissue oxygen extraction (FTOE), using the anterior cerebral 
artery (ACA) and internal carotid artery (ICA) 10 minutes prior to receiving caffeine, 30 
minutes during, and every hour up to 6 hours after receiving caffeine. 
 
They found that caffeine increased oxygen extraction in the brain, which suggested a 
transient stimulating effect on brain metabolism, because cerebral oxygen saturation 
decreased. This could however be due to a decrease in cerebral blood flow or cerebral 
vasoconstriction which might have been pCO2 induced. They also found significant decrease 
in pCO2. Furthermore, they found a significant increase in heart rate and mean arterial blood 
pressure. 
 
No changes were found with regards of brain perfusion nor electrical activity of the brain, 
neither was there any changes in respiration rate (RR) nor SaO2 over time. In the ACA, there 
was a significant decrease in peak systolic velocity (PSV) and Doppler-measured resistance-
index (RI), while end-diastolic velocity (EDV) did not change significantly. No changes in 
Doppler variables were measured in the ICA after caffeine intake. 
 
In 2015, Maitre et al (39) did a study on 45 infants. Their aim was to assess whether or not 
caffeine had an impact on improving cortical differentiation on complex speech sounds. 
They find an improvement in auditory processing probably due to improved 
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neurodevelopmental outcomes. Normally preterm infants show reduced speech sound 
discrimination when compared to term babies. This study however, revealed that preterm 
infants receiving low dose caffeine had a similar perception to that of a more mature infant 
not exposed to caffeine, which suggests that caffeine might improve cortical processing of 
auditory stimuli. Their finding has also been supported from a previous study done by Chen 
et al in 94. (40)  
 
3.5 Caffeine’s effect on premature babies’ sleep  
Curzi-Dascalova et al (41) studied 15 preterm infants regarding caffeine’s influence on sleep. 
10 infants received caffeine, and 5 were controls receiving no caffeine therapy. In both 
caffeine- and non-caffeine-treated babies, the various sleep variables, including 
wakefulness, active and quiet sleep, and total sleep time, were similar before and after the 
caffeine dose (p > 0.2). Oxygen saturation in arterial blood did not drop below 85% in any of 
the infants and healthily altered between 90-97%. They found no significant differences in 
sleep organization between 33- and 34-week PMA infants receiving maintenance-dose 
caffeine citrate (5 mg/kg/day) by matching with control infants. 
 
In 2014, Marcus et al (42) published a double-blind, randomized, controlled clinical trial. 
They included 201 ex-preterm children aged 5–12 years old, 98 of whom had received 
caffeine, and 103 had gotten placebo. This was yet another prospective follow-up study of 
the CAP trial. The hypothesis was that caffeine therapy for AOP would result in long-term 
abnormalities in sleep patterns and breathing during sleep. The children underwent 
actigraphy (recording motor activity), polysomnography, and caregivers fulfilled sleep 
questionnaires. Investigators and families remained blinded as to whether or not the child 
had received caffeine or placebo as a neonate.  
 
A large proportion of children in both groups had obstructive sleep apnea syndrome (OSAS), 
8.2% of the caffeine group and 11.0% of the placebo group. Furthermore, 24% of the 
caffeine group and 29% of the placebo group had either an elevated apnea hypopnea index 
(AHI – being the number of pauses or almost pauses per hour) and/or a history of 
adenoidectomy/tonsillectomy (standard treatment for childhood OSAS). Results showed 
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that sleep questionnaire scores were within the natural range, and did not differ amongst 
the groups, including sleep onset latency and sleep efficiency. No difference was found in 
the restless legs syndrome either.  
 
From 2013 – 2015, the authors from a Finnish study recruited 21 preterm infants at 35,7 
mean GW (43). The aim of the study was to explore the effects of caffeine and supplemental 
oxygen on periodic breathing (PB, consisting of short apnea episodes separated by 
hyperpnoeic episodes) and apnea of prematurity during sleep and NREM (non-rapid eye 
movement) sleep, using polysomnography. Most cases of PB and AOP happened during 
NREM and caused intermittent hypoxia.  
 
The authors found that oxygen supplementation decreased PB time by 99% and caffeine by 
91% (p < 0.001). Further, they observed that a reduction in AOP, from 1.4 per hour at 
baseline to 0.4 with oxygen (p = 0.03) and 0.3 with caffeine (p = 0.07). They concluded that 
preterm infants might likely benefit from a prolonged caffeine treatment to prevent 
intermittent hypoxia.  
 
3.6 Early vs late administration  
A Canadian retrospective observational cohort study on 5517 neonates (approximately same 
gestational age, < 31 GW) by Lodha et al (17) was conducted between 2010-2012. They 
divided neonates from 29 different Canadian neonatal intensive care units (NICUs) into two 
groups; 74.6% receiving early caffeine treatment (within the 2nd day after birth), and 25.4% 
receiving it later (after or on the 3rd day following birth).  
 
The study demonstrated that neonates in the early group had lower odds of composite 
death or BPD with an adjusted odds ratio (AOR) = 0.81, 95% CI 0.67-0.98, as well as PDA, 
AOR = 0.74, 95% CI, 0.62-0.89. No adverse impact on any other outcomes was observed, 
such as NEC, severe neurological injury nor severe retinopathy of prematurity. Furthermore, 
the neonates in the late group stayed longer in the NICUs and they were more likely to 
receive surgical intervention such as mechanical ventilation, high-frequency ventilation, and 
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needed oxygen for a longer time period.  
 
3.7 High vs low dose  
In 2015, Mohammed et al (44) published a randomized, pilot, double-blinded, prospective 
study, comparing two different dose regimens of caffeine citrate in preterm infants in Egypt. 
They compared high-dose (loading 40 mg/kg/day and maintenance of 20 mg/kg/day) vs low-
dose (loading 20 mg/kg/day and maintenance of 10 mg/kg/day) caffeine citrate in preterm 
infants <32 weeks’ gestation, presented with AOP within the first 10 days of life. A total of 
120 neonates (60 in each group) were enrolled. 
 
High-dose caffeine was associated with a significant reduction in extubation failure in 
mechanically ventilated preterm infants (10 out of 30 infants (33 %) vs 13 out of 35 infants 
(37 %) in the high vs low dose caffeine groups, respectively; RR 0.89, 95 % CI 0.46-1.7, p < 
0.05), frequency of apnea (p < 0.001), and days of documented apnea (p < 0.001). High-dose 
caffeine was associated with a significant reduction in the duration of oxygen therapy. 
Nonetheless, high-dose caffeine was associated with a significant increase of tachycardia 
episodes (23 vs 8 %, p < 0.05), but without significant impact on physicians decision to 
withhold caffeine. 
 
The use of higher than current standard dose of caffeine may decrease the chance of 
extubation failure in mechanically ventilated preterm infants and the frequency of AOP 
without significant side effects, giving fewer apnea episodes and less days of documented 
apnea. No significant difference was noted in neonatal mortality, BPD, NEC, IVH, ROP, or 
length of hospital stay between the groups.  
 
3.8 Caffeine vs other Methylxanthines 
In 2017, Khurana et al (45) published a study on 79 children observing long-term 
neurodevelopment outcome at 18 to 24 months of corrected age, after receiving either 
caffeine or aminophylline therapy for AOP ≤34 weeks of gestational age. 43 of whom had 
received caffeine and 36 aminophylline. Cognitive, language and motor deficits were 
assessed by Bayley Scale of Infant and toddler Development (BSID –III). Postnatal 
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characteristics such as hearing and visual impairments during NICU visit were noted and 
followed up. 
 
Infants allocated to the caffeine group showed 84% lower risk of acquiring cognitive 
impairment (RR 0.16, CI 95% 0.02-1.36), 50% lower risk of developing motor deficits (RR 
0.50, CI 95% 0.12-1.95) and 24% lower risk of developing language problems (RR 0.76, CI 
95% 0.36-1.58). Infants received caffeine had 40% lesser risk of developing visual 
abnormalities (RR – 0.60, CI 95% 0.34-1.04). However, in all the neurodevelopment fields, 
the differences between the groups were not statistically significant, including development 
of hearing impairments. Nevertheless, the clinical significance of caffeine over aminophylline 
cannot be overlooked. 
 
Risk of mortality in the caffeine group was 9% lower than in the aminophylline group, 
although statistically non-significant (RR – 0.92, CI 95% – 0.45-1.84, p = 0.81). Incidence of 
mortality was found to be 11.2% in caffeine treated infants where against 12.2% in 
aminophylline group. Physical growth parameters were found to be similar. 
 
In 2009 Skouroliakou et al (46) published a randomized controlled trial viewing differences in 
effect between caffeine and theophylline for treating apnea of prematurity. They enrolled 
70 neonates < 33 weeks’ GA, of whom 33 received caffeine and 37 theophylline. Treatment 
was started if an infant had  3 apneic attacks requiring vigorous intervention within 24 h.  
If < 3 apnea episodes were recorded, prophylaxis was initiated. Therapy with either 
methylxanthine reduced apneic events, most in the caffeine group (p = 0.005), but also in 
the theophylline group (p = 0.012).  
 
Analysis of the caffeine data showed a significant decrease in the number of apneic events 
per day after caffeine administration on days 1–3 (p = 0.001) and 4–7 (p = 0.001). Analysis of 
combined (treatment plus prophylaxis) data showed a significant decrease in apnea 
frequency only in those infants receiving caffeine (p = 0.001). There was, however, no 
sustained benefit of caffeine over theophylline beyond the first week of therapy.  
 
In 2017, Shivakumar et al (47) published a single-center randomized controlled trial from 
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India, comparing the efficacy and safety of caffeine and aminophylline for treating apnea of 
prematurity. They included 240 preterm infants < 34 weeks GA. Half received caffeine and 
the other half aminophylline. Primary outcome was frequency of apneic episodes (number 
of apnea spells per 24 hour) at an interval of 1 to 3 day, 4 to 7 day and 8 to 14 day of 
therapy.  
 
The results showed that apneic episodes during 4-7 days of therapy was found to be 
significantly higher in caffeine group (p = 0.03), although, complete perseverance of apnea 
was attained after median of 6 days in either group. They found no difference in median 
length hospital stay at the NICU between the groups. Furthermore, there was no significant 
difference in the risk of developing feed intolerance (17% vs 22.8%, RR 0.74, 95% CI 0.39-
1.40), jitteriness (8% vs 9%, RR 0.87, 95% CI 0.31-2.49) or glucose abnormality (3% vs 3%, RR 
1.02; 95% CI 0.21-4.92).  
 
Persistent desaturation in caffeine group was higher than that of aminophylline during first 3 
days of therapy (p = 0.006). However, in the second week of therapy, aminophylline group 
reported higher desaturation episodes (p < 0.001). Additionally, aminophylline group had 
higher mean HR on the 2nd day (p = 0.007) and the 3rd day (p = 0.002). Risk of developing 
tachycardia was lower in caffeine vs aminophylline-treated infants (RR 0.30, 95% CI 0.15-
0.60). 
 
In 2018, Shivakumar et al (48) published yet another randomized study trial by looking at 
hemodynamic effects on caffeine vs aminophylline therapy in 185 preterm neonates ≤ 34 
weeks, using echocardiography. Results showed that heart rate was significantly and 
exclusively higher in the aminophylline-treated neonates than the caffeine-treated ones (p < 
0.001). End-systolic volume was higher in both caffeine (p < 0.001) and aminophylline group 
(p = 0.001) compared to pretreatment values. End-diastolic volume was also significantly 
higher in both groups (p = 0.01).  
 
In 2000, Gannon et al (49) compared the use of caffeine citrate with theophylline. They 
concluded that caffeine was the desired drug of choice given its longer half-life, once a day 
dosing interval, fewer side effects, easier monitoring and earlier onset of action. Moreover, 
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it has almost 100% bioavailability given orally, a wider therapeutic window and fluctuates 
less in plasma concentrations compared with theophylline. See table 4 for further 
comparison, and table 5 for additional effects of Methylxanthines (24).  
 
Comparison of Caffeine and Theophylline  
Variable Caffeine Theophylline 
- Efficacy +++ +++ 
- Peripheral side effects +/- +++ 
- Drug clearance Very slow (T1/2 = 100 hours) Slow (T1/2 = 30 hours) 
- Plasma level at steady state Stable Fluctuating 
- Need for drug monitoring +/- +++ 
- Dosing interval Once daily 1-3 times a day 
Table  4: Theophylline or caffeine: which is best for AOP?  
 
 
Major Effects of Methylxanthines                                ↑= increases    ↓= decreases 
- Regularized breathing pattern 
- ↑ ventilator drive 
- ↑ chemoreceptor sensitivity to carbon dioxide 
- ↓ REM sleep 
- ↑ Blood glucose 
- Enhanced diaphragmatic contractility  
- Stimulus of CNS  
- ↑ renal blood flow and ↑ diuresis 
- Augmentation of the basal metabolic rate 
- Stimulation of gastric secretion and ↓ esophageal sphincter tone 
Table  5: Major effects of methylxanthines 
 
In 2006, Natarajan et al published an observational study (50) on 101 premature neonates 
regarding drug monitoring of caffeine plasma concentration. They showed that monitoring 
of plasma concentrations of caffeine is unnecessary, even in extremely premature infants 
with renal or hepatic dysfunction. This was due to the fact that the overwhelming majority 
attained goal plasma levels with current dosing regimens with concentrations in the range of 
5 - 20 mg/L. However, monitoring of plasma levels may be prudent in cases without clinical 




3.9 Prophylactic treatment 
In 2001, Henderson-Smart, DJ and Steer, PA reviewed the evidence (51) on prophylactic use 
of caffeine to prevent apnea, including cyanosis and bradycardia in ex-preterm infants who 
underwent general anaesthesia just before surgery. They included three eligible trials, each 
of which showed that caffeine-treated infants had fewer apnea/bradycardia episodes. The 
estimate for absolute risk difference was -0.58 (95% CI -0.74 - -0.43), i.e. less than two 
infants had to be treated with caffeine to prevent one having postoperative apnea. Caffeine 
also reduced bradycardia and oxygen desaturation after general anaesthesia. The clinical 
importance of this is however unclear given the small population sizes. No adverse effects of 
caffeine were mentioned.  
 
In 2016, Armanian et al (52) published a single-center randomized double-blinded placebo-
control clinical trial study to investigate the preventive effects of caffeine on apnea 
incidence in higher-risk neonates. A total of 52 infants with a birth weight below 1200 g 
were eligible for enrollment. 26 were given caffeine, and 26 infants were controls. The 
preventive effect of caffeine on apnea was significant in these infants. Only 4 infants (15.4%) 
in the caffeine group developed apnea, compared with 16 (61.5%) in the control group (p = 
0.001).  
 
In the caffeine group, two (7.7%) of the neonates developed bradycardia and five (19.2%) 
developed cyanosis, compared to 16 infants (61.5%) that did not receive caffeine (p < 0.05).  
No difference in medication side effect, like tachycardia, was reported in the neonates (p > 
0.99). Only four infants (15.4%) in the caffeine group developed chronic lung disease (CLD; 
defined as dependent on oxygen at 28 days of life), compared to 11 (44.0%) in the placebo 
group (p = 0.025). In conclusion, it appears that less mature infants will have greater benefits 
of prophylactic caffeine on the incidence and severity of apnea.  
 
In 2019, Jain et al published their results from a randomized double blinded trial (53). 
Their aim was to evaluate weather caffeine given in bolus dose of 20 mg/kg followed by 5 
mg/kg would reduce the age of the first successful extubation for ventilated infants.  
They enrolled 110 infants between 23-30 weeks GA requiring mechanical ventilation the first 
5 days of life. The intervention group received early caffeine with a loading dose of 20 mg/kg 
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followed by a 5 mg/kg maintenance dose. The control group received normal saline bolus 
and maintenance dose.  
 
The patients were followed until 36 weeks GA or until discharge or death, whichever came 
first. The trial was stopped early at 75% enrollment (goal 80% power) with 83 infants 
enrolled, due to a persistent, although nonsignificant trend of higher mortality in the early 
caffeine group. They concluded that caffeine given prophylactically does not reduce the age 
of first successful extubation after mechanically ventilation as there were no significant 
outcome differentiation between the two groups. A larger multicenter trial is necessary to 
detect minimal clinically important differences in mortality. Trials terminated early may be 
difficult to interpret. Although ethically appropriate, it can reduce power to detect clinically 
important differences in outcomes.  
 
In 2003, Steer et al (54) published a double-blind randomized dose response trial. The 
primary outcome measure was extubation failure, defined as neonates who were unable to 
be extubated within 48 h of caffeine loading or who required re-ventilation or Doxapram 
within 7 days of caffeine initiation. Continuous recordings of oxygen saturation and heart 
rate were commenced in a subgroup of enrolled infants.  
 
A total of 127 babies were enrolled into the study trial, with 42, 40 and 45 being randomized 
to the 3 mg, 15 mg and 30 mg dose groups of caffeine, respectively. The extubation failure 
rates were found to be 19 (45%), 10 (25%) and 11 (24%), respectively (p = 0.06). The 3 mg 
group had significantly more documented apnoea per group over the 7-day trial than the 
other two dose groups (p < 0.01). The numbers of infants experiencing tachycardia (defined 
as a HR > 200 bpm for four consecutive hourly interval recordings) was 1, 5 and 8 infants in 
the 3 mg, 15 mg and 30 mg groups, respectively, but these differences were not statistically 
significant (p = 0.07).  
 
Infants on the two highest doses of caffeine (15 and 30 mg/kg) recorded a significantly 
higher mean HR and mean SpO2 (p = 0,001 for both). No difference was demonstrated in the 
numbers of infants with major neonatal morbidity (Grade 3 or 4 intraventricular 
haemorrhage, necrotizing enterocolitis, culture proven sepsis, patent ductus arteriosus, 
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pulmonary air leak). 
 
Infants in the two higher dose groups had statistically significantly less documented apnea 
than the lowest dose group (p = 0.01). Of the 37 neonates with continuous pulse oximetry 
recordings, those on higher doses of caffeine recorded a statistically significantly higher 
mean heart rate, oxygen saturations and less time with oxygen saturations <85%.  
 
This trial indicated there were short-term benefits of decreased apnea in the urgent peri-
extubation period for ventilated infants born <32 weeks’ gestation receiving higher doses of 
caffeine. They conclude that a dose of 3 mg/kg per day of caffeine citrate is less effective 
than 15 mg/kg or 30 mg/kg per day for preventing apnoea in infants <32 weeks’ gestation in 








4.1 Summary of main results  
The main purpose of this review was to summarize the available evidence on how effective 
caffeine is for treating AOP, and at the same time look for possible side effects. The most 
important findings were that caffeine reduced BPD in VLBW preterm infants with AOP, the 
need of supplemental oxygen and the need for positive airway pressure. A side effect of 
caffeine therapy was temporarily reduced weight gain (25).  
 
Caffeine citrate was significantly more effective in reducing apnea episodes, by at least 50% 
in 6 days compared to placebo, and approached statistical significance in 3 days. It was also 
significantly better than placebo in eliminating apnea in 5 days, and approached significance 
after 2 days (32).  
 
Furthermore, caffeine therapy for AOP improved the survival rate without 
neurodevelopmental disability at 18 - 21 months in infants with VLBW. Caffeine also reduced 
the incidence of cerebral palsy, death and survival rates with neurodevelopmental disability. 
The incidence of cognitive delay was likewise lower in the caffeine group (26). At 5 years 
follow-up it was a lower percentage of death in the caffeine group, although not statistically 
significant (28). Furthermore, neonatal caffeine therapy for AOP reduced the risk of DCD in 
5-years-old (29). It appears to have a lasting beneficial effect on motor function, both at 18 
months, 5 and 11 years of age (30). 
 
When it comes to heart rate, studies conclude differently. A retrospective observational 
study discovered a significant correlation between caffeine citrate and heart rate (33). 
However, the severity was mostly mild to moderate from 170 – 212 bpm, and the 
physiological effect was minor. Other studies did not find any differences in heart rates (34) 
(55). Yet another study found significant results after 30 minutes of administration in the 




High-dose caffeine was associated with a significant reduction in extubation failure in 
mechanically ventilated preterm infants, frequency of apnea, and days of documented 
apnea. Further, it was associated with a significant reduction in the duration of oxygen 
therapy. Nonetheless, high-dose caffeine was associated with an increase of tachycardia, but 
noteworthy without impact on physicians decision to withheld caffeine therapy (44). 
 
Regarding the effect of caffeine and brain activity, no differences were found in clinical 
seizures nor in cEEG, but a significant increase in aEEG continuity was detected starting half 
an hour after caffeine administration. At 36 weeks’ control, at significantly longer NICU stays 
in the controls not receiving caffeine was found in one study. The authors concluded that 
caffeine increased cerebral cortical activity and resulted in maturation at 36 weeks, without 
risk of seizures (37).  
 
Neonates receiving caffeine early had lower odds of composite death, BPD and PDA. No 
adverse impact on any other outcomes was observed, like NEC, severe neurological injury 
nor severe ROP. Furthermore, the neonates in the early group stayed shorter in the NICUs 
and, they were less likely to receive surgical intervention like mechanical ventilation, high-
frequency ventilation, and also needed shorter periods of oxygen (17). 
 
4.2 Comparison with other studies and reviews  
Other literary reviews support the findings from this review, including Henderson-Smarts´ 
“Methylxanthine treatment for apnoea in preterm infants (Review)”, published in 2010 (56), 
and Moscino et al’s more recent study “Caffeine in preterm infants: where are we in 2020?” 
(23). These reviews together with this one allow for a more precise understanding of the 
effects in these related, but different populations.  
 
The incidence as well as the severity of the clinical apnea is greatest in infants born at earlier 
gestational ages, and therefore it would be expected that they would benefit more from 
treatment (55). The same is true for treating AOP prophylactically (52). McCallum at 
Edinburgh University in Scotland did a clinical review on WHO guidelines behind using 
caffeine for treating AOP prophylactically in otherwise healthy premature infants, and its 
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association with bradycardia and hypoxia. He found fewer episodes of apnea and 
bradycardia in the treated groups at term age compared to the controls. However, his 
conclusion was that bigger studies would be required before supporting the use of caffeine 
prophylactically.  
 
Although a few studies found increased heart rate as a side effect to caffeine for treating 
AOP, a Cochrane review in 2004 (57) of two randomized controlled studies found no 
significant change between caffeine and no-caffeine group in the terms of tachycardia and 
the use of positive airway pressure ventilation. 
 
Gregory D. Funk, a professor at the Department of Physiology at University of Alberta is 
nonetheless losing sleep over the “caffeination” of prematurity, he writes in 2009 (58). He 
worries about the long term side effects caffeine might have on infants, referring to a study 
done by Montandon et al on rats (59). They discovered that a regimen of orally distributed 
caffeine of 15 mg/kg/day from postnatal age 3-12, changed the rats sleep architecture, e.g.  
a 50% latency to sleep onset. It also changed their respiratory control in adulthood with a 
reduced response to increased CO2.  
 
On the other hand, another study concluded that therapeutic neonatal administration of 
caffeine had no long-term side effects on sleep duration nor sleep apnea during childhood. 
However, ex-preterm infants are in general at risk for developing obstructive sleep apnea. A 
limitation with this study was that only a small portion of patients agreed to join the study. 
Henceforth, it is possible that parents with concerns about their child’s sleep may have been 
more ready to consent. Nevertheless, no differences were noted between the caffeine and 
placebo groups (42). 
 
4.3 Biological mechanisms  
The biological proposed mechanism of caffeine’s effect on AOP include amongst other 
things; stimulation of the respiratory center, increased sensitivity to CO2, increased tonus of 
skeletal muscle tone, enhanced contractility of the diaphragm, as well as increased minute 
ventilation, metabolic rate and oxygen consumption. Furthermore, caffeine stimulates the 
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cardiovascular and central nervous system and enhance secretion of catecholamines. It has a 
diuretic effect and alters glucose homeostasis  (13) (60). Some overlap is therefore expected 
in the way caffeine affects both primary and secondary outcomes of this review.  
 
The proposed mechanism of temporary weight gain was thought to be increased oxygen 
consumption with methylxanthines (25). Further, caffeine increased oxygen extraction in the 
brain, which suggests a transient stimulating effect on brain metabolism, because cerebral 
oxygen saturation decreases. This could, however, be due to a decrease in cerebral blood 
flow or cerebral vasoconstriction which might have been pCO2 induced. They also found 
significant decrease in pCO2 (38). 
 
4.4 Strengths   
There are several benefits to this study. A total of 30 articles have been included from a wide 
range of sources, and consequently knowledge on the topic has been summarized. The task 
has been clearly defined and many different variables have been looked at. Further, only 
new articles from the years after 2000 have been included. The study design is modest in the 
way that it uses already existing data, not collecting raw data, as this is a literary review. 
Besides, the study is less resource-intensive when it comes to planning, since most work is 
based around the systematic search and reading articles.  
 
While a lot of the articles included in this review have smaller sample sizes, most can be 
applied to a bigger population. RCTs usually have lesser external validity, but since the 
population studied here is so narrow, that is premature babies with apnea, they too provide 
a higher external validity. Further, most studies included are RCTs with superior quality 
compared to for example case control studies.  
 
Even though this study may not provide a complete answer to the research question, it will 
hopefully be of great help and value for others going further into investigation on the same 
subject. The study has been cautiously written with the ignorant reader in mind. Thus, the 
transparency of this review makes it simple to recreate. Moreover, being “systematic” offers 
a sense of thoroughness.  
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4.5 Limitations  
Writing a literary review brings some disadvantages on its own. They are very much 
restricted to the accessibility of sources. It is thus an inevitable chance to overlook important 
“grey” literature. While MeSH terms are a great way to include a vast amount of articles, 
chances are not all articles of interest will appear in a search.  
 
The possible lack of quality in each article included in this review, provides further 
disadvantages to the finishing review. All study designs were included in the systematic 
search, most of them were RCTs, and only a few were purely observational, with RCTs being 
the gold standard, and observational studies lowers the overall quality.  
 
As the infant's lungs and central respiratory control mature, AOP most often resolves on its 
own, which makes it more of a developmental disorder rather than a disease (61). AOP is 
also increasingly more common in premature infants, and compulsorily improves with age, 
even without treatment. With this in mind, studies are of lesser value without controls. 
Subsequently, all of the studies in this review had controls. 
 
4.6 Summary of GRADE evaluation  
Many articles have accounted for most of the checklist questions, making it easier to grade 
them – from very low to high quality based on their study designs. It was a criterion of 
writing the master thesis to grade at least five articles (see attachments). Four of the studies 
chosen were RCTs and one was a cohort. The RCTs start with high initial quality while the 
cohort starts with low. Of the four RCTs, one article remained high grade, two were 
downgraded to moderate and one to low.  
 
Some of the reasons for downgrading were small population sizes, lack of follow-up data, 
missing detail information and in general not enough information and transparency. The 
cohort studied remained of a low quality. It had a large study population, but did not 
mentioned basic details about background of study-infants, it had some inconsistency in the 
protocol of early caffeine use, potential variations in the maintenance dose, and it did not 






Caffeine has played an important role over the past four decades going from invasive to non-
invasive support treating AOP. In preterm infants, caffeine is effective in reducing AOP, the 
need for ventilation and given early reduces the time stayed at the NICUs. Caffeine-treated 
preterm babies have lower rates of BPD, IVH and PDA, and have optimistic long-term 
outcomes on neurodevelopment and respiratory functions. Few adverse events have been 
identified to cause long-term adverse effects. 
 
Additional larger studies are necessary to detect less common adverse effects, although the 
ones included are adequate to show the effect on AOP. Moreover, longer follow-up studies 
than 11 years would be of great value for possibly long-standing adverse effects. In order to 
indicate which infants are most likely to benefit from this treatment, there is need for 
stratification by for example GA and birth weight and other risk factors for future studies.  
 
As caffeine has been the golden standard for the past four decades, it is safe to say it has a 
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